Articles tagged with: Daratumumab
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago came to an end yesterday.
The fourth day of the meeting, which was Monday, was the busiest day in regard to myeloma-related research. It started with an oral presentation session that included seven talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday’s oral presentation session. A later article will cover the findings from the afternoon poster session.
This year’s American Society of Clinical Oncology (ASCO) annual meeting began yesterday morning in Chicago and will run through Tuesday.
Myeloma-related presentations were made during two sessions yesterday.
One session was designed to better educate physicians about personalized therapy for elderly patients with lymphoid malignancies. During that session, Dr. Tanya Marya Wildes from the Washington University School of Medicine in St. Louis talked about how to navigate treatment options for older multiple myeloma patients.
The key myeloma-related research presented yesterday was made public during a poster session in the afternoon …
The American Society of Clinical Oncology will hold its 50th annual meeting May 30 through June 3 in Chicago.
Similar to previous years, more than 25,000 physicians and researchers from all over the world are expected to attend the five-day meeting to discuss the current research in cancer treatment and care.
During the meeting, there will be presentations about all areas of cancer, including many focused specifically on multiple myeloma. The ASCO website currently lists information about more than 60 myeloma-related studies (included under either the “multiple myeloma” or “
The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more …
This year’s meeting of the American Society of Hematology (ASH) began yesterday morning in New Orleans.
Myeloma-related presentations were made during several sessions yesterday.
Two sessions were designed to better educate physicians about multiple myeloma and how to treat the disease.
The key myeloma-related research presented yesterday was made public during a poster session in the evening about the biology of myeloma as well as preclinical and clinical studies testing new and existing treatments for myeloma.
During the session, research results were made available for review by meeting attendees in …